Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure

Nat Cancer. 2025 Sep;6(9):1524-1536. doi: 10.1038/s43018-025-00982-7. Epub 2025 May 20.

Abstract

Chimeric antigen receptor (CAR) T cell therapy is one of the most promising cancer treatments. However, different hurdles are limiting its application and efficacy. In this context, how aging influences CAR-T cell outcomes is largely unknown. Here we show that CAR-T cells generated from aged female mice present a mitochondrial dysfunction derived from nicotinamide adenine dinucleotide (NAD) depletion that leads to poor stem-like properties and limited functionality in vivo. Moreover, human data analysis revealed that both age and NAD metabolism determine the responsiveness to CAR-T cell therapy. Targeting NAD pathways, we were able to recover the mitochondrial fitness and functionality of CAR-T cells derived from older adults. Altogether, our study demonstrates that aging is a limiting factor to successful CAR-T cell responses. Repairing metabolic and functional obstacles derived from age, such as NAD decline, is a promising strategy to improve current and future CAR-T cell therapies.

MeSH terms

  • Age Factors
  • Aging* / immunology
  • Aging* / metabolism
  • Animals
  • Female
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Mice
  • Mitochondria / metabolism
  • NAD* / metabolism
  • Receptors, Chimeric Antigen* / immunology
  • Receptors, Chimeric Antigen* / metabolism
  • T-Lymphocytes* / immunology
  • T-Lymphocytes* / metabolism

Substances

  • NAD
  • Receptors, Chimeric Antigen